Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,126 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Regimen Clear all
Completed Phase 2 Interventional

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

NCT00002415
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

NCT00413660
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
33
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Upland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 3, 2026, 5:36 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 3, 2026, 5:36 AM EDT
Completed No phase listed Observational

A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021

NCT01498497
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
EUR-1100, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 3, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

NCT05182476
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Luvadaxistat
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Bryant, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT01620489
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Concord, California • La Jolla, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 3, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 3, 2026, 5:36 AM EDT
Terminated Phase 3 Interventional

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

NCT00197197
View directory record Official record
Conditions
HIV Infection
Interventions
GW873140
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
Los Angeles, California • Norwalk, Connecticut • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

NCT02513550
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 3, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

NCT01479465
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

NCT03052751
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
UCB7665, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 3, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 5:36 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 3, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

NCT07079761
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
Behavioral · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432
View directory record Official record
Conditions
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions
Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)

NCT00475800
View directory record Official record
Conditions
Osteoarthritis
Interventions
Lumiracoxib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Timeline
Started 2004
U.S. locations
5
States / cities
Tucson, Arizona • Brooklyn Park, Minnesota • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 3, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801
View directory record Official record
Conditions
Crohn's Disease
Interventions
IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
87
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8

NCT00218036
View directory record Official record
Conditions
Cocaine Abuse, Opiate Dependence
Interventions
Modafinil 200mg, Modafinil 400mg, Citalopram 20mg, Citalopram 40mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
22 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Managing Opioid Related Sleep Apnea With Acetazolamide

NCT06043830
View directory record Official record
Conditions
Sleep-Disordered Breathing, Obstructive Sleep Apnea, Central Sleep Apnea, Chronic Pain, Opioid Use
Interventions
Acetazolamide, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 3, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Study of REGN3500 and Dupilumab in Patients With Asthma

NCT03112577
View directory record Official record
Conditions
Asthma, Allergic
Interventions
REGN3500, Dupilumab, Placebo, Fluticasone propionate
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 3, 2026, 5:36 AM EDT
Terminated Phase 3 Interventional

Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens

NCT00603577
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Xaliproden
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 3, 2026, 5:36 AM EDT